All in all, our molecular results suggest that BRAF/MEK inhibition could create an oncogenic environment in certain tissues, potentially via compensatory activation of alternative mitogenic pathways, such as FGFR3 or RAS-MAPK signaling, which are more commonly involved in BC oncogenesis. Here, FGFR3 is linked to breast cancer.